Highlights
- Market Cap
- $3.24B
- Enterprise Value
- $3.19B
- EPS (TTM)
- -$1.61
- EBITDA (TTM)
- -$191.41M
- Year Range
- $10.60 - $32.80
- Target Price
- $30.00
- ROA (TTM)
- -30.36%
- ROE (TTM)
- -32.13%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Edgewise Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Edgewise Therapeutics Inc (EWTX) has returned 26.94% so far this year and 43.18% over the past 12 months.
Edgewise Therapeutics Inc
- 1D
- 4.03%
- 1M
- 3.48%
- YTD
- 26.94%
- 6M
- 94.20%
- 1Y
- 43.18%
- 3Y*
- 67.78%
- 5Y*
- 0.97%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 26, 2021, EWTX's average daily return is +0.13%, while the average monthly return is +1.83%. At this rate, your investment would double in approximately 3.2 years.
Historically, 44% of months were positive and 56% were negative. The best month was Dec 2023 with a return of +79.9%, while the worst month was Mar 2023 at -30.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, EWTX closed higher 49% of trading days. The best single day was Sep 19, 2024 with a return of +54.7%, while the worst single day was Sep 13, 2022 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.44% | 8.13% | 3.48% | 26.94% | |||||||||
| 2025 | 4.94% | -6.60% | -15.93% | -25.45% | -12.93% | -8.19% | 8.77% | 0.63% | 13.03% | 12.70% | 42.45% | -4.70% | -7.06% |
| 2024 | 62.98% | -8.41% | 11.70% | -1.64% | -4.52% | 5.14% | -5.44% | 10.10% | 42.35% | 25.78% | -1.70% | -19.09% | 144.06% |
| 2023 | 14.43% | -6.35% | -30.38% | 31.48% | 15.39% | -23.42% | -5.94% | -14.27% | -8.32% | 11.69% | -5.00% | 79.93% | 22.37% |
| 2022 | -10.99% | -13.31% | -17.73% | -17.73% | -21.68% | 27.36% | 21.48% | 4.24% | -2.38% | -3.35% | -5.89% | -0.11% | -41.49% |
| 2021 | 8.33% | -11.88% | 0.80% | -26.12% | -17.91% | -9.54% | 4.80% | -0.60% | 5.58% | -12.28% | -49.07% |
Benchmark Metrics
Edgewise Therapeutics Inc has an annualized alpha of 18.91%, beta of 1.36, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 29, 2021.
- This stock participated in 82.58% of S&P 500 Index downside but only 48.41% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 18.91%
- Beta
- 1.36
- R²
- 0.08
- Upside Capture
- 48.41%
- Downside Capture
- 82.58%
Return for Risk
Risk / Return Rank
EWTX ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Edgewise Therapeutics Inc (EWTX) and compare them to a chosen benchmark (S&P 500 Index).
| EWTX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.55 | 0.90 | -0.34 |
Sortino ratioReturn per unit of downside risk | 1.30 | 1.39 | -0.08 |
Omega ratioGain probability vs. loss probability | 1.18 | 1.21 | -0.03 |
Calmar ratioReturn relative to maximum drawdown | 0.74 | 1.40 | -0.66 |
Martin ratioReturn relative to average drawdown | 1.31 | 6.61 | -5.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore EWTX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Edgewise Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Edgewise Therapeutics Inc was 84.69%, occurring on Nov 10, 2023. Recovery took 248 trading sessions.
The current Edgewise Therapeutics Inc drawdown is 13.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.69% | Mar 30, 2021 | 661 | Nov 10, 2023 | 248 | Nov 6, 2024 | 909 |
| -68.81% | Nov 7, 2024 | 106 | Apr 11, 2025 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Edgewise Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Edgewise Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EWTX in comparison with other companies in the Biotechnology industry. Currently, EWTX has a P/B value of 6.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |